Silexion Therapeutics Reveals Synergistic Efficacy of SIL-204 in Combination with Chemotherapy for Pancreatic Cancer

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNA...

January 17, 2025 | Friday | News
Pioneer Group Partners with Thermo Fisher to Empower Biotech Startups in Healthcare and Sustainability

Pioneer Group has  announced a collaboration agreement with Thermo Fisher Scientific to support biotech founders on their journey towards commerci...

January 16, 2025 | Thursday | News
GSK to Acquire IDRx for $1 Billion to Advance Precision Therapies for GIST

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx)  announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, c...

January 14, 2025 | Tuesday | News
Xentria Expands Global Clinical Trials and Biosimilar Portfolio in 2025

Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical needs, announced operational expansion ...

January 09, 2025 | Thursday | News
Lilly’s Pirtobrutinib Shows Strong Efficacy in Phase 3 BRUIN CLL-321 Trial for BTK-Inhibitor Pre-Treated CLL/SLL Patients

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...

December 10, 2024 | Tuesday | News
Amgen’s BLINCYTO® Significantly Improves Disease-Free Survival in Pediatric B-ALL, Redefining Standard of Care

Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...

December 09, 2024 | Monday | News
Nxera Pharma Launches Phase 3 Trial of QUVIVIQ™ (Daridorexant) in South Korea to Address Insomnia Epidemic

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...

December 05, 2024 | Thursday | News
Pfizer Appoints Dr. Chris Boshoff to Lead Global R&D Strategy, Pursuing Breakthroughs in Oncology and Beyond

Pfizer Inc. (NYSE: PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, a...

November 21, 2024 | Thursday | News
Quotient Sciences Installs World’s First GMP Biofoundry-in-a-Box for Accelerated RNA Manufacturing

" Quotient Sciences, in collaboration with Centillion, has installed the revolutionary Biofoundry-in-a-Box (BiaB™) at its Alnwick site, marking a n...

November 20, 2024 | Wednesday | News
Abzena Expands Analytical Capabilities with GMP Cell-Based Potency Assays at Cambridge and San Diego Facilities

" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...

November 20, 2024 | Wednesday | News
AstraZeneca’s Tagrisso (osimertinib) Recommended for EU Approval in Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...

November 19, 2024 | Tuesday | News
Tirzepatide Significantly Reduces Heart Failure Risk in Obese Patients with Preserved Ejection Fraction, New Data Show

Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...

November 18, 2024 | Monday | News
GSK’s Blenrep Combination Demonstrates Significant Survival Benefit in Relapsed/Refractory Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...

November 15, 2024 | Friday | News
GenScript Biotech Global Forum 2024: Paving the Way for Innovation and Investment in Cell and Gene Therapy

- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...

November 14, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close